Xospata Dosage

Patient Selection

Select patients for the treatment of AML with XOSPATA based on the presence of FLT3 mutations in the blood or bone marrow.

•

Interrupt XOSPATA if severe signs and/or symptoms persist for more than 48 hours after initiation of corticosteroids.

•

Resume XOSPATA when signs and symptoms improve to Grade 2* or lower.

Posterior Reversible Encephalopathy Syndrome

•

Discontinue XOSPATA.

QTc interval greater than 500 msec

•

Interrupt XOSPATA.

•

Resume XOSPATA at 80 mg when QTc interval returns to within 30 msec of baseline or less than or equal to 480 msec.

QTc interval increased by >30 msec on ECG on day 8 of cycle 1

•

Confirm with ECG on day 9.

•

If confirmed, consider dose reduction to 80 mg.

Pancreatitis

•

Interrupt XOSPATA until pancreatitis is resolved.

•

Resume XOSPATA at 80 mg.

Other Grade 3* or higher toxicity considered related to treatment.

•

Interrupt XOSPATA until toxicity resolves or improves to Grade 1*.

•

Resume XOSPATA at 80 mg.